Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Non Operating Income (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Non Operating Income for 8 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non Operating Income rose 107.61% to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $92.8 million, a 1946.83% increase, with the full-year FY2024 number at $3.8 million, down 38.93% from a year prior.
  • Non Operating Income was $1.8 million for Q3 2025 at Whitehawk Therapeutics, down from $2.1 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $88.2 million in Q1 2025 to a low of -$1.4 million in Q1 2021.
  • A 5-year average of $5.5 million and a median of $1.2 million in 2024 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: crashed 807.7% in 2021, then soared 7114.55% in 2025.
  • Whitehawk Therapeutics' Non Operating Income stood at -$46000.0 in 2021, then skyrocketed by 3469.57% to $1.5 million in 2022, then dropped by 6.77% to $1.4 million in 2023, then plummeted by 53.22% to $676000.0 in 2024, then surged by 166.27% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Non Operating Income are $1.8 million (Q3 2025), $2.1 million (Q2 2025), and $88.2 million (Q1 2025).